Recently, the United States Food & Drug Administration (FDA) has approved the use of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) for metastatic castration-resistant PCa [2]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.